Aromatase inhibitors pharmacological importance
DOI:
https://doi.org/10.24959/ubphj.16.73Keywords:
aromatase inhibitors, letrozole, anastrozoleAbstract
This review is devoted to the different generations aromatase inhibitors characteristics, their place in clinical practice and in the cancer treatment. Drugs from this group are able to inactivate aromatase enzyme, and causes estrogen synthesis inhibition. High effective and selective aromatase inhibitors of 3rd generation, have recently entered the market, could compete with tamoxifen - "gold standard" of the breast cancer management. A successful clinical trials of letrozole and anastrozole have identified new approaches to the treatment of estrogen-dependent cancers and to the enlargement of the scope of these drugs using.References
Краснопольская К. В. Первый опыт использования ингибитора ароматазы анастрозола в программе ЭКО при лечении бесплодия / К. В. Краснопольская, А. С. Калугина. — Проблемы репродукции. — 2001. — Т. 7, № 6. — С. 42–46.
Ляшенко А.А. Интракринология: о роли локальной ферментативной биотрансформации эстрогенов в норме и при патологи / А.А. Ляшенко, О.Ю. Алексеева, А.А. Захаров. — Проблемы репродукции. — 2009. — № 6. — С. 33–36.
Молотков, А.С. Возможности применения ингибиторов ароматазы в терапии генитального эндометриоза / А.С. Молотков, М.И. Ярмолинская. — Журнал акушерства и женских болезней. — 2011. — Т. LX, № 4. — С. 117-125.
Морчиладзе А.З. Применение непрямых индукторов овуляции при нормогонадотропной ановуляции / А.З. Морчиладзе, В.В. Потин., М.А. Тарасова. — Журнал акушерства и женских болезней. — 2010. — Т. LIX, № 3. — С. 22–32.
Назаренко Т.А. Ингибиторы ароматазы в репродуктивной медицине / Т.А. Назаренко, Д.В. Дмитриев— Проблемы репродукции. — 2007. — Т. 1. — С. 14–20.
Adjuvant exemestane with ovarian suppression in premenopausal breast cancer / [Pagani O. et al.]. — New Engl. J. Med. — 2014. — 371, 107–118.
Bone fractures among postmenopausal patients with endo-crine-responsive early breast cancer treated with 5 years of letrozole or tamoxifen in the BIG 1-98 trial / [Rabaglio M. et al.]. — Annals of oncology. — 2009. — Vol. 20, N 9. — P. 1489– 1498.
Brueggemeier R.W. Aromatase inhibitors in the treatment of breast cancer / R.W. Brueggemeier, J.C. Hackett, E.S. Diaz-Cruz. — Endocr Rev. —. 2005. —26:331-45.
Bulun S.E. Ovulation induction in women with infertility: a new indication for aromatase inhibitors / S.E. Bulun. — Fertility and sterility. — 2003. — Vol. 80, N 6. — P. 1338–1339.
Clemett D. Exemestane a review of its use in postmenopausal women with advanced breast cancer / D. Clemett, H.M. Lamb. — Drugs. — 2000. —59:1279-96.
Cocconi G. First generation aromatase inhibitors - aminoglutethimide and testolactone / G. Cocconi. — Breast cancer Res Treat. — 1994. — 30, 57-80.
Effect of an aromatase inhibitor on BMD and bone turnover markers: 2-year results of the Anastrozole, Tamoxifen, Alone or in Combination (ATAC) trial (18233230) / [Eastell R., Hannon R.A., Cuzick J. et al.]. — J Bone Miner Res. — 2006. — 21:1215–1223.
Endometrial safety of third generation aromatase inhibitors versus tamoxifen in breast cancer patients / [Morales L. et al.]. — International Journal of Gynecological Cancer. — 2006. — Vol. 16, suppl. 2. — P. 515–517.
Fadrozole HCL (CGS-16949A) versus megestrol acetate treatment of postmenopausal patients with metastatic breast carcinoma / [Buzdar A.U., Smith R., Vogel C. et al.]. — Cancer. — 1996. — 77, 2503-2513.
History of aromatase: saga of an important biological mediator and therapeutic target / [Santen R.J., Brodie H., Simpson E.R. et al.]. — Endocr Rev. — 2009. — 30:343–375.
Jiang W. Motion and flexibility in human cytochrome P450 aromatase. / W. Jiang, D. Ghosh. — PLoS One. — 2012. — 7(2):e32565.
Letrozole suppresses plasma estradiol and estrone sulphate more completely than anastrozole in postmenopausal women with breast cancer / [Dixon J.M., Renshaw L., Young O. et al.]. — J Clin Oncol. — 2008. — 26:1671–1676.
Randomized Phase II neoadjuvant comparison between letrozole, anastrozole, and exemestane for postmenopausal women with estrogen receptor-rich stage 2 to 3 breast cancer: clinical and biomarker outcomes and predictive value of the baseline PAM50-based intrinsic subtype ACOSOG Z1031 / [Ellis, M. J. et al.] — J. Clin. Oncol. — 2011. — 29, 2342–2349.
Recanatini M. Nonsteroidal aromatase inhibitors: recent advances / M. Recanatini, A. Cavalli, P. Valenti. — Med Res Rev. — 2002. — 22:282-304.
Ronde W. Aromatase inhibitors in men: effects and therapeutic options / W. Ronde, F.H. Jong. — Repro Biol Endocrinol. — 2011. — 9:93.
Significant improved survival with Arimidex (anastrozole) versus megestrol acetate in postmenopausal advanced breast cancer: updated results of two randomized trial / [Buzdar A.U., Jonat W., Howell A., et al.]. — Proc. ASCO, 1997, 16, 156, abstr.545.
Simpson D. Letrozole: a review of its use in postmenopausal women with breast cancer / D. Simpson, M.P. Curran, C.M. Perry. — Drugs. — 2004. — 64(11):1213-30.
Stein R. The basis of hormonal therapy of cancer. In: Oxford Textbook of Oncology/ R. Stein, C. Coombes, A. Howell; Ed. M. Peckham et al. — Oxford Medical Publication. — 1995. 629-648.
Downloads
Published
Issue
Section
License
Copyright (c) 2016 National University of Pharmacy
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish with this journal agree to the following terms:- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
